ReviewExperimental & molecular medicine2026
Mitophagy in pathogenesis and therapeutic implications for infection.
Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mitophagy, a critical selective autophagy pathway targeting dysfunctional mitochondria, is involved in cellular homeostasis and quality control under various stressors. During infection, invading pathogens cause mitochondrial abnormalities that trigger mitophagy. Most bacteria and viruses can exploit mitophagy as a pro-pathogenic process to escape host antiviral responses during infection. Emerging evidence suggests that restoring mitophagy is beneficial for mitigating excessive inflammation, such as in sepsis, whereas mitophagy blockade can activate host defense during bacterial and viral infections. Here we review current knowledge on the role of mitophagy in bacterial and viral infections and sepsis, focusing on the mechanisms by which pathogens evade mitophagy or influence pathogenesis through mitophagy during different types of infection. We also highlight the potential beneficial effects of mitophagy modulators, reagents and small molecules against sepsis-induced pathologies and infections. Progress in these areas will expand our knowledge on alleviating pathology, promoting antimicrobial immune responses and maintaining cellular homeostasis, ultimately providing potential preventive and therapeutic strategies against pathogenic infections and inflammation associated with dysregulated mitophagy.
Identifiers
42834108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.